Inactive Instrument

News Coeptis Therapeutics, Inc. OTC Markets

Equities

COEP

US19207C1045

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on receiving the 2024 Chancellor s Distinguished Research Award	Apr. 03	AQ
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award	Apr. 02	PR
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	Feb. 27	AQ
Coeptis Therapeutics Holdings, Inc. Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	Feb. 26	CI
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	Feb. 07	PR
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-In-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	Feb. 07	CI
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024	Jan. 04	PR
Coeptis Therapeutics to Present at the Emerging Growth Conference	Dec. 04	PR
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Coeptis Therapeutics Holdings, Inc. announced that it has received $2 million in funding	Nov. 02	CI
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023	23-10-31	PR
Coeptis Therapeutics Announces $2 Million Private Placement	23-10-24	PR
Coeptis Therapeutics Holdings, Inc. announced that it expects to receive $2 million in funding	23-10-23	CI
Coeptis Therapeutics : Private Placement - Form 8-K	23-10-13	PU
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	23-10-11	PR
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	23-10-11	CI
Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies	23-10-09	PR
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting	23-10-04	PR
Coeptis Therapeutics Holdings, Inc. announced that it expects to receive $0.5 million in funding	23-09-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Coeptis Therapeutics, Inc. OTC Markets

Equities

COEP

US19207C1045

Summary

Filters